1. Introduction {#sec0005}
===============

Antibody responses to neutralize human immunodeficiency virus-1 (HIV-1) are mediated by direct binding to viral spikes, which are trimers composed of glycoproteins gp120 and gp41 ([@bib0515], [@bib0520], [@bib0070], [@bib0455], [@bib0435], [@bib0510], [@bib0255], [@bib0365], [@bib0110], [@bib0745], [@bib0155], [@bib0445]). GP120 with the attachment of virus particles to the target cells, and the gp41 engages in virus-cell fusion ([@bib0185], [@bib0160], [@bib0145], [@bib0065], [@bib0540]). While successful *in-vitro*, recombinant gp120 has failed to generate cross neutralizing antibodies *in vivo* possibly due to the natural conformation of gp120 ([@bib0530], [@bib0740], [@bib0175], [@bib0170], [@bib0825], [@bib0765], [@bib0750], [@bib0550]). Monoclonal antibodies were first generated in mice in 1975 using a hybridoma technique ([@bib0505], [@bib0265], [@bib0055], [@bib0525], [@bib0005], [@bib0440]), and were subsequently accepted globally by manufacturers. Now, it is well understood that rodent and murine derived antibodies are immunogenic in humans; when binding to antigens within the human body, the complexes can be recognized as immunogenic agents. To solve this problem, human equivalent forms were generated from rodent or murine antibodies, known as humanized antibodies ([@bib0495], [@bib0760], [@bib0555], [@bib0060], [@bib0245]). In recent years, new techniques have evolved to isolate human monoclonal antibodies against HIV-1 directly which offer an advantage of reduced immunogenicity.

A panel of HIV-1 specific potent broadly neutralizing antibodies has been isolated in recent decades. The first generation antibodies, 2F5, 2G12 and 4E10, were used in combination for passive immunization ([@bib0460], [@bib0425], [@bib0020]). A second generation antibody, IgG b12, was observed to neutralize numerous virus isolates with IC50 in nM level (1 nM is equal to about 0.15ug/ml) for the first time ([@bib0360], [@bib0120], [@bib0025], [@bib0850], [@bib0665]). The new generation of potent broadly neutralizing antibodies, including VRC01-class antibodies, NIH45-46, PG9/16,10E8, BG18, IOMA, 35O22, ACS202, can neutralize virus isolates ranging from 73% to 98% with IC50 less than 50 μg/ml, and can neutralize 59%--72% of virus isolates with IC50 less than 1 μg/ml ([@bib0450], [@bib0275], [@bib0105], [@bib0685], [@bib0545], [@bib0190], [@bib0150], [@bib0490], [@bib0775], [@bib0595], [@bib0590]).

Worth noting, broadly neutralizing antibody 10E8 neutralizes 98% of tested viruses with geometric mean IC50 of 0.22 μg/ml. 10E8 binds to the cell-surface envelope as opposed to phospholipids. The binding of 10E8 and MPER reveals a highly conserved gp41-hydrophobic residue and a critical arginine or lysine just before the transmembrane region. The breadth and potency of 10E8 demonstrates a conserved site for HIV neutralization and potential target for HIV vaccine design ([@bib0275]). The highly potent VRC01-class broadly neutralizing antibodies (bnAbs) individually neutralize up to 90% of HIV-1 isolates. VRC01-class antibodies are considered a sub group of bnAbs and have already been isolated from several HIV-1 infected patients. They each neutralize different virus isolates through the interaction with HIV gp120 CD4 binding site. VRC01-class bnAbs are derived from human VH1-2 gene family, which occupies 2% of the human antibody repertoire. Structural studies revealed that these VRC01-class Abs interact with gp120 CD4 binding site by mimicking the CD4 molecule; specifically the secondary structure formed by heavy chain structure and CDR3 in light chain. Additionally, an important deletion in CDRL1 present in many VRC01-class Abs can facilitate the interaction with the CD4 binding site and avoid conflict with glycan at Asn^276^ (N276) on loop D ([@bib0825], [@bib0215], [@bib0780], [@bib0830]). Next-generation sequencing (NGS)-derived sequencing reveals that VRC01 lineage is comprised of at least six distinct heavy chain clades and five light chain clades. This observation suggests that extraordinary variation in antibody immunity may only occur within a few antibody lineages − or even a single lineage ([@bib0780]). Generation of an unmutated common ancestor of VRC01-class antibodies could be a potential mechanism for opposing HIV-1. After stimulation by virus and co-evolution with the virus, the unmutant common ancestor has ability to mature to bnAbs.

Human antibodies can be elicited by B cells to eliminate "foreign immunogens" directly or indirectly. Some antibodies can be produced to neutralize foreign antigens by various mechanisms, while some non-neutralizing antibodies can perform effector functions such as mediating NK cells via antibody-dependent cellular cytotoxicity (ADCC) ([@bib0365], [@bib0370], [@bib0690], [@bib0285], [@bib0395]). Serum immunoglobulins produced naturally by human immunity have been applied in passive immunotherapy against many infectious diseases since 1990. But this approach suffers a number of problems. Not only have these polyclonal immunoglobulins displayed mixed efficacies, but they also pose the potential threat of blood-borne pathogen transmission. In addition, the resource of serum is limited and expensive. These disadvantages limit the application of polyclonal immunotherapy ([@bib0050], [@bib0645], [@bib0735], [@bib0610], [@bib0340]). Recent technology developments have made it possible to isolate human antibodies against HIV-1 from both *in vivo* and *in vitro* sources. These improved techniques include display methods, Epstein-Barr virus (EBV) immortalization, classical hybridoma procedures, and single-cell sorting followed by molecular cloning.

2. Techniques to make human monoclonal antibodies {#sec0010}
=================================================

2.1. Hybridoma technique, B cell immortalization and microneutralization {#sec0015}
------------------------------------------------------------------------

In the mid-1970s, hybridoma technology was invented for production of mouse monoclonal antibodies with defined antigen specificities and neutralization activity for application in clinical therapies ([@bib0310], [@bib0280], [@bib0705], [@bib0410], [@bib0260], [@bib0270], [@bib0290]). Hybridomas can be generated by effective fusion of B cells and partner cells followed by screening of individual antibody producing cells. Production of monoclonal antibody in individual hybridoma cells can be easily quantified by surface plasmon resonance imaging ([@bib0650]). B cell hybridomas can be an important source for screening of monoclonal antibodies. High-throughput screening is used to characterize mouse IgG antibodies; including sub-isotypes, binding activity, and neutralizing activities ([@bib0375], [@bib0675]). Fluorescent antigen can be used to sort antigen binding hybridoma cells from a mixture as opposed to the traditional way of screening using multi-micro well plate screening and limiting dilution. As an extension of this technology, T cell hybridoma was also generated ([@bib0325]). However, mouse monoclonal antibodies were shown to be problematic in humans due to their immunogenic properties and low effector function. High immunogenicity prevented their application in humans where prolonged dosing was required. Differences in sequence and glycosylation pattern of the Fc region make rodent mAbs poorly effective in mediating effector functions in human ([@bib0350]). Human B cells proved to be difficult to immortalize using hybridoma technique ([@bib0350], [@bib0125], [@bib0500]). The primary issue was that mAbs produced by human B cell hybridoma cells could react against self-antigens. In addition, the lack of sufficient maturation outside of the germinal centers and low binding affinities of mAbs derived by hybridoma, meant that only 1.5% of screened clones typically reacted to the target antigen. Due to these problems, antibody humanization was developed as an alternative to generate human format antibodies from rodent derived antibodies ([@bib0405], [@bib0140], [@bib0480], [@bib0575], [@bib0720], [@bib0475]). Humanized antibodies are produced by methods of genetic engineering and can potentially reduce the immune response against non-human derived antibodies. This is done by combining the variable (V) region binding domain of a rodent antibody with human antibody constant (C) regions. This kind of chimeric antibody retains the binding specificity with less immunogenicity to humans. In some cases, the chimeric antibodies retain the effects in mediating human complement-dependent cytotoxicity (CDC) or ADCC. It is also possible to produce a humanized antibody without creating a chimeric intermediate first. Once the precise sequences of the desired CDRs are known, these DNA sequences can be directly cloned into antibody expression vectors with human antibody "scaffold". A wide variety of human antibody expressing vectors has been developed using this method. For example, PDR12 vector is a human IgG1 antibody expressing vector which was originally used for expression of human HIV-1 potent neutralizing antibody IgG b12. Antibody VRC01 was cloned into a different cloning vector described previously by Tiller et al. ([@bib0695]).

Another method to immortalize human memory B cells is by Epstein-Barr virus (EBV) mediated transformation ([@bib0345], [@bib0315], [@bib0660], [@bib0470], [@bib0420], [@bib0710]). The C3b, EBV-binding receptor positive B cells can be immortalized to generate antibodies for isolation using single cell sorting, or can be cultured with feeder cells for further screening or cloning. The optimized methodology is to activate B cells using Toll-like receptor 9 (TLR9) agonist CpG DNA before or during EBV infection, which has been used to isolate human monoclonal antibodies against various pathogenic viruses ([@bib0300], [@bib0035], [@bib0670]). It has also been reported that human B cells can be immortalized by transforming a retrovirus encoding anti-apoptotic factor B cell lymphoma 6 (BCL6) and BCL-XL in the presence of interleukin 21 (IL-21) and CD40 ligands ([@bib0600], [@bib0570], [@bib0330]). This process can trigger memory B cells to differentiate into antibody secreting cells. The immortalization of human B cells provides a substantial resource of human B cells for the subsequent screening. After culturing for 1--2 weeks, antibodies can be collected and isolated from the supernatant to perform neutralization against different viruses. Immortalized B cells can also be sorted by antigen using flow-based technology, and the heavy and light chain genes of antibodies secreted by immortalized B cells can then be cloned. The famous 2G12, 2F5 and 4E10 antibodies are generated by this method ([@bib0115]). However, due to the low efficiency of EBV-induced B cell transformation, this method has limitation in application. Though optimization methods were studied based on EBV-induced B cell transformation, the efficiency still needs a dramatic improve ([@bib0670], [@bib0385], [@bib0335]). Some reports show that memory B cells can be cultured short-term, and the supernatant can be used directly for screening of neutralization activity in a high throughput neutralization assay (micro-neutralization). A number of famous neutralizing antibodies have been isolated based on these methods including PG9, PG16, PGT121-128 and 10E8 ([@bib0275], [@bib0545], [@bib0730], [@bib0725], [@bib0200]).

HIV-1 potent neutralizing antibodies PG9 and PG16 are classic antibodies isolated by microneutralization. These were originally isolated from 30,000 activated memory B cells from one clade A infected donor screened from approximately 1800 characterized HIV infected donors. The memory B cells were cultured at clonal density for the purpose of cloning antibody heavy and light chain pair from each culture well. PG9 neutralized 127 out of 162 viral isolates and PG16 neutralized 119 out of 162 viruses with a median potency (IC50) less than 0.2 μg/ml. 10E8 is an anti-gp41 antibody isolated from 16,500 memory B cells, sorted and cultured with IL-2, IL-21, and CD40-ligand expressing feeder cells. 10E8 neutralized 98% of the tested pseudoviruses with an IC50 below 50 μg/ml, and 72% of the tested viruses with an IC50 values below 1 ug/ml.

B cell culture and microneutralization can isolate potent broadly neutralizing HIV-1 antibodies. However, the large scale screening of B cells makes this method labor intensive and costly, in addition to low yield; typically ten antigen-specific clones can be isolated out of ten thousands of B cells ([Fig. 1](#fig0005){ref-type="fig"} A and B). In current reports, EBV transformation was optimized with efficiency from 0.1%-2% to 7.8%, which enabled the generation of immortalized B cell libraries. However the efficiency still needs to be improved to enable greater B cell survival ([@bib0670]).Fig. 1Methods currently used in human monoclonal antibody screening.Fig. 1

2.2. Phage/yeast display {#sec0020}
------------------------

Phage display is a library method which permits screening of antibodies from a large recombinant library ([@bib0200], [@bib0080], [@bib0135], [@bib0010], [@bib0535], [@bib0205]). Antibodies can be displayed in the form of either single chain variable fragments (ScFv) or antigen-binding fragments (Fab). Recent reports show that single domain antibody can also be displayed in phage display system ([@bib0180], [@bib0305], [@bib0355], [@bib0560], [@bib0680]). Many antibodies against different viruses including rabies virus, severe acute respiratory syndrome (SARS) virus, Ebola virus, yellow fever virus, hepatitis C virus, dengue virus, hepatitis A virus, influenza virus, and HIV, have been successfully isolated using this technology. The principle for phage display technique in isolating antibodies is to construct a phage display recombinant antibody library first. Recombinant antibody library can increase the diversity of antibodies in B cell repertoires, which promotes the screening of antibodies with novel properties ([@bib0230]). Antibody libraries are in general constructed by randomly assembling antibody heavy and light chain variable region, and through gene shuffling of the heavy and light chain to further increase the diversity. In summary, phage display creates greater diversity of antibodies and provides rapid and high throughput way of screening.

M43 and m44 are HIV-1 cross-reactive human monoclonal antibodies isolated from a recombinant phage display library by competitive antigen panning ([@bib0820], [@bib0815], [@bib0810], [@bib0800], [@bib0805]). M44 is a gp41 specific cross-reactive antibody, and m43 can recognize both gp120 and gp41. B12 is another potent neutralizing antibody isolated by phage display from recombinant antibody libraries, and it is considered one of the most potent neutralizing antibodies isolated by phage display, as it can neutralize about 40% of known HIV-1 isolates ([@bib0360], [@bib0400], [@bib0250], [@bib0770]). M43, m44 and b12 can be considered standard antibodies isolated by phage display; however the potencies are much lower than antibodies isolated by micro neutralization, such as PG9/16 and/or 10E8.

Phage display selects antibodies *in vitro*, and antibodies expressed in phage system may not necessarily represent those in mammalian cells due to the difference in protein folding and post transcriptional modifications. It is difficult to draw direct conclusions and gain an understanding of the natural occurrence of antibody heavy and light chain selection based on phage display alone ([@bib0795]). To avoid these limitations, other display methods have been developed to display antibodies on the surface of yeast or mammalian cells, which can be sorted by flow cytometry according to antigen specificity. This is known as yeast surface display, which has become a powerful engineering tool for displaying recombinant proteins on the surface of *Saccharomyces cerevisiae* via genetic fusion ([@bib0715], [@bib0430], [@bib0015], [@bib0605], [@bib0220], [@bib0075]). Yeast surface display is a eukaryotic expression system with the capability to induce post translational modifications on recombinant antibodies. Each yeast cell expresses fusion recombinant proteins which allows for the application of cell sorting for a specific antigen. Yeast display system was not only reported used for isolation of antibodies, but also reported to be used in displaying antigens and other recombinant proteins ([@bib0635], [@bib0240]). There is a panel of yeast display antigen library which has been constructed, including yeast display H1N1 antigen epitope library, and yeast display SIV antigen epitope library for epitope mapping.

HIV-1 specific antibodies isolated by display techniques are less potent than those isolated by micro neutralization or single B cell sorting and cloning. However in recent studies, phage/yeast display showed great potentials in isolating single domain antibodies from recombinant libraries. Single-domain antibodies are considered a separate class of antibodies composed of antibody fragments consisting of a single monomeric antibody domain. Single-domain antibodies allow a broad range of applications due to their small molecular mass and size, efficient production, and high affinity. Single domain antibodies can be labeled using fluorescent molecules for diagnostic purpose or biotechnological usage. With the conjunction of drug or toxin, single domain antibodies can also be used for therapeutic application. The most well-studied single domain antibodies are antibody heavy-chain variable domains. The DNA sequence will be optimized in order to improve the stability. In addition to heavy-chain variable domains, there are other types of single domain antibodies which have been studied, including CH2 antibodies, and light-chain variable domain antibodies, and some other forms of nanobodies ([@bib0180], [@bib0355], [@bib0225], [@bib0380], [@bib0390], [@bib0090], [@bib0085], [@bib0095]).

Mammalian cell display is a powerful method for the isolation of antibodies in scFv format or full length IgG with high affinity. It has been shown that single chain antibodies can be displayed on the surface of human HEK-293T cells and used for affinity maturation ([@bib0615], [@bib0700], [@bib0045]). Mammalian cell expression system ensures that all of the cellular components will be involved in process of antibody synthesis. Isolation of human antibodies by mammalian cell display can benefit from the advantages of mammalian cell expression system.Mammalian cell display relies on the transfection of antibody expression vectors. In comparison with the yeast display system, mammalian cell expression system allows multiple recombinant protein/antibody delivering vectors in one cell. Thus a further modification, enrichment, and single clone isolation will be needed for panning purposes ([Fig. 1](#fig0005){ref-type="fig"}C).

2.3. Flow cytometry based single cell sorting and cloning {#sec0025}
---------------------------------------------------------

An important advance in antibody screening and cloning technology is the development of single cell sorting and single cell reverse transcription PCR ([@bib0485], [@bib0195], [@bib0040]). Human single B cells with different antigen specificities can be sorted by flow cytometer directly, and the original VH and VL pairing of the antibody from single human B cells can be amplified in a high efficient way, with the requirement of relatively few cell numbers. This methodology is quite efficient in obtaining antibody heavy and light chain from extremely rare and highly discrete B cell subpopulations ([Fig. 1](#fig0005){ref-type="fig"}D). Memory B cells and plasma cells are ideal cell types for the purpose of monoclonal antibody cloning due to the specificity of the cell types. This method is always combined with single cell cloning after flow cytometry based single cell sorting to sort the antigen specific B cells, thus accurate probe design for sorting is essential.

The gp120 or gp41 proteins are not ideal probes, because they are reactive with many HIV-1 antibodies, including non-neutralizing but strong binding antibodies ([@bib0775], [@bib0780], [@bib0835]). One successful example of probe design in fishing potent broadly neutralizing HIV-1 monoclonal antibodies is the agents' pair of RSC3 and ΔRSC3. RSC3 and ΔRSC3 are computer-assisted designed for sorting of individual B cells expressing CD4bs antibodies. The resurfaced stabilized core 3 (RSC3) is a functional structure core of the CD4 binding site with loop deletion. RSC3 preserved the antigenic structure of the CD4 binding site and eliminated other antigenic regions by substitution with simian immunodeficiency virus (SIV) or non--HIV-1 residues. ΔRSC3 contains one amino acid deletion (at position 371) in RSC3. This single amino acid mutation can knock out the function of CD4 binding site. CD4 binding site antibodies like VRC01 and b12 can bind efficiently with RSC3 but fail to bind with ΔRSC3. Potent broadly neutralizing antibody VRC01 is isolated through the single B cell positive sorting by RSC3 and negative sorting by ΔRSC3. VRC01 neutralized up to 90% of the tested pseudoviruses with an IC50 below 50 μg/ml, and 70% of the tested viruses with an IC50 values below 1 ug/ml ([@bib0775], [@bib0780], [@bib0415]).

BG18, IOMA are another two successful bnmAbs isolated by reasonable probe design and single cell sorting/cloning ([@bib0235], [@bib0210]). N-glycans on the trimeric envelope glycoprotein (Env) can be accommodated by broadly neutralizing antibodies. An engineered crystal structures of the HIV-1 Env trimer with an exposed native glycan shield of high-mannose and complex-type N-glycans was used to fishing out the bnmAbs. IOMA, a new CD4-binding site (CD4bs) antibody was thus defined. The heavy chain of IOMA derives from VH1-2\*02, which is considered the germline gene of VRC01-class bNAbs, but its light chain lacks the short CDRL3 which defines VRC01-class bNAbs. BG18, BG1, and NC37 are three bNAbs isolated by single IgG+ B cell sorting by using four different fishing agents in four separate sorts: 2CC core, gp140YU2, a 1:1 mixture of gp14092UG37.8 (clade A) + gp140CZA79012 (clade C), and BG505 SOSIP.664 ([@bib0620], [@bib0165], [@bib0785], [@bib0580], [@bib0320]). Antibody BG18 (VH4-4 and VL3-25) targeted the glycan-V3 portion of envelope, can neutralize 64% of viruses in a 118-virus panel tested with a geometric mean IC50 of 0.03 mg/ml. Antibodies NC37 (VH1-46/1-2, VK3-20) and BG1 (VH3-49 and Vk1-49) showed geometric mean IC50 of 0.3 and 0.67 mg/ml respectively. NC37 can bind to a quaternary trimer epitope, the core of which overlaps with the CD4bs, and BG1 binds to the V1V2 region.

Antigen baiting and fishing has proven quite successful in isolating HIV-specific human monoclonal IgG expressing B cells and IgM expressing B cells from infected donors using cleverly engineered antigen probes. Flow cytometry based single cell sorting and cloning can also be applied in understanding the natural selection of antibodies by cloning of antibodies in B cells from different infection stage from one donor or B cells in the same stage from different donors. 454 deep sequencing allows for the study of the maturation of a specific antibody population and corresponding B cell subpopulations by the stimulation of virus isolates in progressingstages of infection ([@bib0465], [@bib0030], [@bib0130], [@bib0295], [@bib0630], [@bib0655], [@bib0845], [@bib0840]).

2.4. HIV-1 specific bNAbs isolation from immunized animals {#sec0030}
----------------------------------------------------------

The difficulty in eliciting bNAbs in immunized animals has been concluded ([@bib0730], [@bib0580], [@bib0625]). The enormous antigenic diversity of the envelope glycoprotein and the N-linked glycan shield are considered as two major points. Recent study shows that success of rapid elicitation of broadly neutralizing antibodies to HIV-1 by immunization in cows. JR-FL gp120 and BG505 SOSIP are immunized to cows, and strong immune response is observed. And broadly neutralizing antibodies were isolated from peripheral blood mononuclear cells (PBMCs) by sorting with biotinylated BG505 SOSIP. The broadly neutralizing antibody NC-Cow1 displayed a 72% neutralization breadth with a potent median IC50 of 0.028 μg /ml on a 117-virus panel tested.This study gives lights in investigating the generation of antibodies against pathogens that have evolved to avoid human antibody responses in animals.

3. Conclusion {#sec0035}
=============

In recent decades, the technology advances have allowed for specific human antibodies to be isolated directly from human B cells and/or from recombinant libraries. These isolated human monoclonal antibodies can be used in therapy because of their safety, efficiency, specificity and tolerance in humans; thus are a powerful tool in fighting against pathogens. Among the developed antibody isolation methods over the last decade, it is difficult to highlight one as the sole preferred method. Different methodology has different advantages. Display techniques basing on recombinant library can be used for isolating single domain antibodies with enlarged library size. But this technique cannot provide us the information of the original pair of heavy chain and light chain of a specific antibody. Single B cell sorting and culturing facilitate the rapid cloning of potent neutralizing antibodies with the requirement of large labor cost. Reasonable design of probes and the development of native-like stabilized trimers have greatly improved efficiency in screening of functional envelope-binding B cells. Thus it is hard to conclude the best way to generate novel bnAbs. Combined methods can be used in screening and isolating potent neutralizing antibodies in order to maximize the advantages of different methods. Meanwhile, the development of novel methodology of broadly neutralizing antibodies isolation and screening are encouraged to broaden our knowledge and enlarge the recourses of antibody classes. A purposed method basing on single cell sorting and viral neutralization instead of fishing agents should provide a direct and efficient way to minimum the workload.

In addition to passive treatment and presentation, another important purpose of isolation and characterization of potent broadly neutralizing antibodies is the functional study of neutralizing epitopes which provides key knowledge for efficient vaccine design. Human broadly neutralizing antibodies serve as a potential source of discovering neutralizing epitopes that can be targeted to fight against many infectious diseases and can thus facilitate the design of the vaccines. Antibody structure studies can provide new insights into the mechanism of recognition of immune evasion epitopes at the atomic level, and how antibodies mature to capture the virus mutant ([@bib0450], [@bib0755], [@bib0565]). However in recent reports, few immunogen candidates were reported that can elicit potent broadly neutralizing antibodies in several immunization studies. Native-like HIV-1 envelope trimers BG505 SOSIP.664 and B41 SOSIP.664 are reported to induce neutralizing antibodies against the Tier-2 virus in rabbits, even though the potency is much weaker in comparison to the broadly neutralizing antibodies isolated from human long term non-progressors ([@bib0585], [@bib0100]).Pre-stimulation of B cells by heterogenous epitopes or antigens showed improved stimulation of B cells in generating potent neutralizing antibodies ([@bib0790]). It has also been reported that PGT121-class germline-targeting stabilized trimer immunogens primed PGT121-like responses in PGT121 inferred-germline knock in mice, highlighting the hypothesis of prime-boosting and sequential immunization strategy ([@bib0640]). All these observations highlight the neutralizing antibodies' role in HIV-1 prevention. Altogether, understanding antibody generation and function mechanisms can help to guide efficient vaccine design and produce effective therapy.
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